The Technical Analyst
SciSparc Ltd. [SPRC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
SciSparc Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.22% $1.320
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.24 mill |
| EPS: | -326.40 |
| P/E: | 0 |
| Earnings Date: | Aug 07, 2023 |
| SharesOutstanding: | 2.45 mill |
| Avg Daily Volume: | 1.346 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 2/22 | 3/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.939 - 1.701 ( +/- 28.86%) |
| ATR Model: 14 days |
Forecast:
16:00 - $1.340
Live Trading Signals (every 1 min)
Forecast
1: 15:54 - $1.328
Forecast 2: 16:00 - $1.340
Forecast 3: 16:00 - $1.340
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.320 (-2.22% ) |
| Volume | 0.0771 mill |
| Avg. Vol. | 1.346 mill |
| % of Avg. Vol | 5.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SPRC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 14:54 | sell | $3.75 | N/A | Active |
|---|
SPRC
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Latest Press Releases
2024-04-11 08:15:00 - Press Release
Scisparc To Acquire Automax
Tel aviv, israel, april 11, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “agreement”) with automax motors ltd. (“automax”), a leading vehicle importer company in israel.
2024-03-27 08:55:00 - Press Release
Scisparc- Clearmind Collaboration Evolves With New International Patent Application For Preventing And Treating Depression
Tel aviv, israel, march 27, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with clearmind medicine inc. (“clearmind”) (nasdaq: cmnd) (cse: cmnd) (fse: cwy), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, clearmind has submitted a patent application under the international patent cooperation treaty.
2024-03-21 08:58:00 - Press Release
Scisparc: Mitocarex Unveils Groundbreaking Discovery Of Small Molecule Structure In Anti-cancer Research
Mitocarex bio dedicates efforts to creating a predictive ai model to predict small molecules more efficiently tel aviv, israel, march 21, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that mitocarex bio ltd.
2024-03-18 07:29:00 - Press Release
Scisparc Granted Another Patent, Strengthening Its Core Technology In Canada
Tel aviv, israel, march 18, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (“company” or “scisparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the canadian intellectual property office (the “patent”). the patent aligns seamlessly with the company's proprietary technology and is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.
2024-03-14 08:49:00 - Press Release
Scisparc Achieves Major Milestone With First Patient Dosed In Autism Spectrum Disorder Clinical Trial
First patient has been dosed in the randomized, controlled, double blind clinical trial for autism spectrum disorder in pediatric patients
Latest News
2024-01-24 13:49:42 - InvestorPlace
Why Is SciSparc (SPRC) Stock Up 50% Today?
Cannabinoid biotech specialist SciSparc (NASDAQ: SPRC ) is enjoying a much-needed boost on Wednesday thanks to a key investment deal. This morning, management announced an equity purchase agreement with a private-equity fund, reflecting confidence in the otherwise embattled business.
2023-12-13 14:02:48 - InvestorPlace
Why Is SciSparc (SPRC) Stock Up 25% Today?
Shares of drug discovery specialist SciSparc (NASDAQ: SPRC ) are popping sharply today on encouraging clinical study results. Specifically, the company's joint venture (JV) project MitoCareX Bio achieved positive results regarding small-molecule screening processes.
2023-11-24 10:47:00 - Market Watch
SciSparc's stock stays hot after biopharmaceutical company sets merger deal
SciSparc Ltd.'s stock SPRC was up 74% on Friday, two days after the clinical-stage biopharmaceutical company said it agreed to merge with an unnamed company in Israel.
2023-11-22 09:49:13 - InvestorPlace
Why Is SciSparc (SPRC) Stock Up 20% Today?
SciSparc (NASDAQ: SPRC ) stock is rising higher on Wednesday as investors react to the company signing a letter of intent for a merger. That merger would be with a leading vehicle importer company in Israel that goes unnamed in the SciSparc press release.
2023-11-15 10:55:57 - InvestorPlace
Why Is SciSparc (SPRC) Stock Up 47% Today?
SciSparc (NASDAQ: SPRC ) stock is taking off on Wednesday after the company released results from a Phase IIa trial of SCI-110 as an Alzheimer's Disease agitation treatment. The clinical trial covered 18 patients with Alzheimer's who have been dealing with agitation symptoms.
2023-10-31 11:08:39 - InvestorPlace
Why Is SciSparc (SPRC) Stock Up 58% Today?
SciSparc (NASDAQ: SPRC ) stock is taking off on Tuesday after the pharmaceutical company posted positive patent news. The big news here is the company's patent for ‘Combination of Opioids and N-Acylethanolamines for pain treatment” getting approval from IP Australia.
2023-10-17 08:00:39 - InvestorPlace
Why Is SciSparc (SPRC) Stock Up 105% Today?
SciSparc (NASDAQ: SPRC ) stock is rising higher on Tuesday after the pharmaceutical company regained listing compliance. SciSparc notes that the Nasdaq Exchange has closed a complaint against the company concerning the price of its shares.
2023-06-07 20:56:18 - InvestorPlace
The 7 Most Promising Penny Stocks to Buy in June
Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.
2023-06-01 13:07:39 - PennyStocks
Hot Penny Stocks To Watch After UCAR Stock Explodes
If there's one thing we know now it's that catalysts play a significant role in trading penny stocks. This is where things like sympathy sentiment can play a much larger role.
2023-02-19 11:00:00 - PennyStocks
The Role of Fundamental Analysis in Penny Stock Investing
How fundamental analysis helps investing in penny stocks The post The Role of Fundamental Analysis in Penny Stock Investing appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.